These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1750784)

  • 1. Vascular access thrombosis in epoetin alfa therapy.
    Binkley LS
    ANNA J; 1991 Dec; 18(6):540. PubMed ID: 1750784
    [No Abstract]   [Full Text] [Related]  

  • 2. Vascular access thrombosis in epoetin alfa therapy.
    Leonard DK
    ANNA J; 1991 Aug; 18(4):371-6; discussion 377. PubMed ID: 1872636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list.
    Akman B; Afsar B; Ataç FB; Ibis A; Arat Z; Sezer S; Ozdemir FN; Haberal M
    Transplant Proc; 2006 Mar; 38(2):413-5. PubMed ID: 16549134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vascular access and anemia in hemodialysis].
    Fernández-Gallego J; López V; Toledo R; Martín Reyes G
    Nefrologia; 2004; 24(5):504-5. PubMed ID: 15648912
    [No Abstract]   [Full Text] [Related]  

  • 5. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin does not increase clotting in vascular accesses.
    Besarab A; Medina F; Musial E; Picarello N; Michael H
    ASAIO Trans; 1990; 36(3):M749-53. PubMed ID: 2252802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation.
    Ataç B; Yakupoğlu U; Ozbek N; Ozdemir FN; Bilgin N
    Transplant Proc; 2002 Sep; 34(6):2030-2. PubMed ID: 12270302
    [No Abstract]   [Full Text] [Related]  

  • 8. The periodicity of vascular access thrombosis revisited: TIS the season.
    Diskin ChJ
    Nefrologia; 2007; 27(6):767-8. PubMed ID: 18336112
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is hyperhomocysteinaemia a risk factor for recurrent vascular access thrombosis in haemodialysis patients?
    Ducloux D; Pascal B; Jamali M; Gibey R; Chalopin JM
    Nephrol Dial Transplant; 1997 Sep; 12(9):2037-8. PubMed ID: 9306379
    [No Abstract]   [Full Text] [Related]  

  • 11. Vascular access thrombosis--what are the possibilities of intervention?
    Mysliwiec M
    Nephrol Dial Transplant; 1997 May; 12(5):876-8. PubMed ID: 9175037
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial.
    Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND
    Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [About the infrequent thrombotic events during erythropoietin therapy of anemia in ovarian cancer patients treated with chemotherapy].
    Lehoczky O; Pulay T
    Orv Hetil; 2007 Nov; 148(44):2081-5. PubMed ID: 17959551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients.
    Manns BJ; Burgess ED; Parsons HG; Schaefer JP; Hyndman ME; Scott-Douglas NW
    Kidney Int; 1999 Jan; 55(1):315-20. PubMed ID: 9893142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent venous thrombosis associated with permanent internal jugular vein hemodialysis catheters.
    Domoto DT; Garvin PJ
    ASAIO Trans; 1987; 33(3):140-3. PubMed ID: 3675936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombosis and occlusion of vascular access in hemodialyzed patients.
    Montagnana M; Meschi T; Borghi L; Lippi G
    Semin Thromb Hemost; 2011 Nov; 37(8):946-54. PubMed ID: 22198859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 1: Focus on Epoetin alfa patient management and recombinant DNA technology.
    Latham D; Nichols E
    ANNA J; 1990 Aug; 17(4):311-4. PubMed ID: 2396857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase and dialysis therapy.
    Twardowski ZJ
    Kidney Int; 2000 Jan; 57(1):345. PubMed ID: 10712113
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacologic intervention to prevent hemodialysis vascular access thrombosis: the next generation of treatment?
    Diskin CJ
    Kidney Int; 2005 Jun; 67(6):2505. PubMed ID: 15882303
    [No Abstract]   [Full Text] [Related]  

  • 20. Arteriovenous fistula thrombosis in patients on regular hemodialysis: a report of 171 patients.
    Roozbeh J; Serati AR; Malekhoseini SA
    Arch Iran Med; 2006 Jan; 9(1):26-32. PubMed ID: 16649374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.